Vestal Point Capital, LP: ENLIVEN THERAPEUTICS INC (ELVN): Quarterly 13F Position History
As of Q2 2026, Vestal Point Capital, LP reported 4,000,000 shares of ENLIVEN THERAPEUTICS INC (ELVN), worth $203.0M and representing 4.7% of its 13F equity book. Quarter-over-quarter share count change: + 750,000 (+23.1%) . The position first appeared in Q2 2025 and has been disclosed across 5 13F-HR filings in Pactolio's tracked window.
- 4,000,000Shares Held (Latest Filing)
- $203.0MReported Market Value (Latest Filing)
- 4.7%Portfolio Weight (% of 13F Equity Book)
- +750,000Quarter-over-Quarter Share Change
- +$75.6MQuarter-over-Quarter Value Change
- 4,000,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 5 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,000,000 | +750,000 | +23.1% | $203.0M | 4.7% | $50.8 |
| Q1 2026 | 3,250,000 | 580,000 | -15.1% | $127.4M | 3.6% | $39.2 |
| Q4 2025 | 3,830,000 | +2,670,000 | +230.2% | $59.0M | 2.2% | $15.4 |
| Q3 2025 | 1,160,000 | +910,000 | +364.0% | $23.7M | 1.1% | $20.5 |
| Q2 2025 | 250,000 | – | – | $5.0M | 0.3% | $20.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Vestal Point Capital, LP first disclose a ELVN position in 13F-HR filings?
Vestal Point Capital, LP first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 5 reported quarters within Pactolio's tracked window.
What was Vestal Point Capital, LP's most recent quarter-over-quarter share-count change in ELVN?
Between Q1 2026 and Q2 2026, Vestal Point Capital, LP added 750,000 shares of ELVN (+23.1%), bringing the total reported position to 4,000,000 shares at a market value of $203.0M.
Does the implied price-per-share represent Vestal Point Capital, LP's cost basis in ELVN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.